A novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma (RRMM): Updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3 bispecific antibody).
Por:
Rodriguez-Otero, P, D'Souza, A, Reece, DE, van de Donk, NWCJ, Chari, A, Krishnan, AY, Martin, TG, Mateos, MV, Morillo, D, Hurd, DD, Rosinol, L, Balari, AS, Wasch, R, Vishwamitra, D, Lin, SXW, Prior, T, Vandenberk, L, Smit, MAD, Rocafiguera, AO and Dholaria, BR
Publicada:
1 jun 2022
Resumen:
Filiaciones:
Clin Univ Navarra, Madrid, Spain.
Med Coll Wisconsin, Milwaukee, WI USA.
Princess Margaret Canc Ctr, Toronto, ON, Canada.
Vrije Univ Amsterdam, Amsterdam Univ, Med Ctr, Amsterdam, Netherlands.
Mt Sinai Sch Med, New York, NY USA.
City Hope Comprehens Canc Ctr, Duarte, CA USA.
UCSF, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA.
Univ Hosp Salamanca, IBSAL, CIBERONC, CIC, Salamanca, Spain.
Hosp Univ Fdn Jimenez Diaz, Madrid, Spain.
Wake Forest Baptist Hlth, Comprehens Canc Ctr, Winston Salem, NC USA.
Univ Barcelona, Hosp Clin, IDIBAPS, Barcelona, Spain.
Univ Barcelona, Inst Catala Oncol Hosp, IDIBELL, Barcelona, Spain.
Freiburg Univ, Med Ctr, Freiburg, Germany.
Janssen Res & Dev, Spring House, PA USA.
Janssen Res & Dev, Antwerp, Belgium.
Janssen Res & Dev, Los Angeles, CA USA.
Hosp Badalona Germans Trias & Pujol, Barcelona, Spain.
Vanderbilt Univ, Med Ctr, Nashville, TN USA.
|